Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.59 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.46 |
| ▸ | FEN1 | P39748 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
| ▸ | KAT7 | O95251 | 2/20 | 0.41 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12758505 | 1.00 | SCN9A (0.59) | SCN9AALOX5APFEN1MEN1ALDH1A1 | |
| SCHEMBL14022204 | 1.00 | SCN9A (0.59) | SCN9AALOX5APFEN1MEN1ALDH1A1 | |
| SCHEMBL12758503 | 0.94 | SCN9A (0.51) | SCN9AALOX5APFEN1GPR119RBP4 | |
| SCHEMBL1142586 | 0.94 | SCN9A (0.51) | SCN9AALOX5APFEN1GPR119RBP4 | |
| SCHEMBL1142219 | 0.90 | SCN9A (0.46) | SCN9AALOX5APFEN1GPR119RBP4 | |
| SCHEMBL13906271 | 0.83 | SCN9A (0.51) | SCN9AALOX5APFEN1CHEK2GPR119 | |
| SCHEMBL1111331 | 0.83 | SCN9A (0.51) | SCN9AALOX5APFEN1CHEK2GPR119 | |
| SCHEMBL1142786 | 0.82 | EPHA2 (0.47) | SCN9AGPR119 | |
| SCHEMBL12758506 | 0.82 | EPHA2 (0.47) | SCN9AGPR119 | |
| SCHEMBL3325111 | 0.80 | SCN9A (0.58) | SCN9AALOX5APFEN1CHEK2RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071125-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110039819-A1 | SUBSTITUTED PHENOXYBENZAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-17 | — | — | US | disclosed |
| US-20090082328-A1 | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071125-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | MKI67, CDK4, VHL | SCN9A 4716/4885ALOX5AP 2059/4885FEN1 2225/4885 |
| US-20110039819-A1 | SUBSTITUTED PHENOXYBENZAMIDES | CCNB3, VEGFA, CCND2 | SCN9A 3613/4885ALOX5AP 2290/4885FEN1 3318/4885 |
| US-20090082328-A1 | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity | MKI67, CDK4, VHL | SCN9A 4716/4885ALOX5AP 2059/4885FEN1 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.